Viral Hepatitis

You have full text access to this OnlineOpen article

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand†

  1. Gail V. Matthews1,‡,§,*,
  2. Anchalee Avihingsanon2,‡,
  3. Sharon R. Lewin3,4,
  4. Janaki Amin1,
  5. Rungsun Rerknimitr5,
  6. Panusit Petcharapirat5,
  7. Pip Marks1,
  8. Joe Sasadeusz6,
  9. David A. Cooper1,
  10. Scott Bowden7,
  11. Stephen Locarnini7,
  12. Kiat Ruxrungtham2,8,
  13. Gregory J. Dore1

Article first published online: 11 AUG 2008

DOI: 10.1002/hep.22462

Issue

Hepatology

Hepatology

Volume 48, Issue 4, pages 1062–1069, October 2008

Additional Information

How to Cite

Matthews, G. V., Avihingsanon, A., Lewin, S. R., Amin, J., Rerknimitr, R., Petcharapirat, P., Marks, P., Sasadeusz, J., Cooper, D. A., Bowden, S., Locarnini, S., Ruxrungtham, K. and Dore, G. J. (2008), A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology, 48: 1062–1069. doi: 10.1002/hep.22462

Author Information

  1. 1

    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia

  2. 2

    HIV–Netherlands Australia Thailand Red Cross AIDS Research Centre, Bangkok, Thailand

  3. 3

    Infectious Diseases Unit, The Alfred Hospital, Melbourne, Australia

  4. 4

    Department of Medicine, Monash University, Melbourne, Australia

  5. 5

    Division of Gastroenterology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

  6. 6

    Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, Australia

  7. 7

    Victorian Infectious Diseases Reference Laboratory, Melbourne, Australia

  8. 8

    Division of Allergy and Clinical Immunology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

  1. ‡

    These authors contributed equally to this study.

  2. §

    fax: (61)-2-9385-0876

*Viral Hepatitis Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia

  1. †

    Potential conflict of interest: Dr. Ruxrungtham advises, is on the speakers' bureau of and received grants from MSD Pharmaceuticals. He is on the speakers' bureau of and received grants from GlaxoSmithKline. He also received grants from Gilead. Dr. Dore advises, is on the speakers' bureau of, and received grants from Gilead. Dr. Locarnini is a consultant for, advises, and received grants fro, Evivar Pty Ltd and Gilead. He is a consultant for and owns stock in Pharmasset. He is also a consultant for Bristol-Myers Squibb. He holds intellectual property rights for and receipt royalties from Melbourne Health. Dr. Sasadeusz is a consultant for, is on the speakers' bureau of, and received grants from Gilead. Dr. Cooper advises, is on the speakers' bureau of, and received grants from Gilead.

Publication History

  1. Issue published online: 26 SEP 2008
  2. Article first published online: 11 AUG 2008
  3. Manuscript Accepted: 3 JUN 2008
  4. Manuscript Received: 4 MAR 2008

Funded by

  • Gilead Sciences. Grant Number: Clinical trial number NCT00192595

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (188K)

References

  • 1
    Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593–601.
  • 2
    Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921–1926.
  • 3
    Puoti M, Bruno R, Soriano V, Donato F, Gaeta GB, Quinzan GP, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 2004; 18: 2285–2293.
  • 4
    Salmon-Ceron D, Lewden C, Morlat P, Bevilacqua S, Jougla E, Bonnet F, et al. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J Hepatol 2005; 42: 799–805.
  • 5
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 74–80.
  • 6
    Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004; 39: 129–132.
  • 7
    Chongsrisawat V, Yoocharoen P, Theamboonlers A, Tharmaphornpilas P, Warinsathien P, Sinlaparatsamee S, et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 2006; 11: 1496–1502.
    Direct Link:
  • 8
    Sungkanuparph S, Vibhagool A, Manosuthi W, Kiertiburanakul S, Atamasirikul K, Aumkhyan A, et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J Med Assoc Thai 2004; 87: 1349–1354.
  • 9
    Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007; 45: 507–539.
    Direct Link:
  • 10
    Brook MG, Gilson R, Wilkins E. BHIVA guidelines on HIV and chronic hepatitis: coinfection with HIV and hepatitis B virus infection. HIV Med 2005; 6(Suppl 2): 84–95.
    Direct Link:
  • 11
    Soriano V, Puoti M, Bonacini M, Brook G, Cargnel A, Rockstroh J, et al. Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel. AIDS 2005; 19: 221–240.
  • 12
    Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS 2006; 20: 863–870.
  • 13
    Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. AIDS 2002; 16: 2352–2354.
  • 14
    Nelson M, Portsmouth S, Stebbing J, Atkins M, Barr A, Matthews G, et al. An open-label study of tenofovir in HIV-1 and hepatitis B virus co-infected individuals. AIDS 2003; 17: F7–F10.
  • 15
    Dore GJ, Cooper DA, Pozniak AL, DeJesus E, Zhong L, Miller MD, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185–1192.
  • 16
    Benhamou Y, Fleury H, Trimoulet P, Pellegrin I, Urbinelli R, Katlama C, et al. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients. HEPATOLOGY 2006; 43: 548–555.
    Direct Link:
  • 17
    Dore GJ, Cooper DA, Barrett C, Goh LE, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999; 180: 607–613.
  • 18
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743–1751.
  • 19
    Ayres A, Locarnini S, Bartholomeusz A. HBV genotyping and analysis for unique mutations. Methods Mol Med 2004; 95: 125–149.
  • 20
    Yuen LK, Ayres A, Littlejohn M, Colledge D, Edgely A, Maskill WJ, et al. SeqHepB: a sequence analysis program and relational database system for chronic hepatitis B. Antiviral Res 2007; 75: 64–74.
  • 21
    Theamboonlers A, Tangkijvanich P, Pramoolsinsap C, Poovorawan Y. Genotypes and subtypes of hepatitis B virus in Thailand. Southeast Asian J Trop Med Public Health 1998; 29: 786–791.
  • 22
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001–1010.
  • 23
    Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–2695.
  • 24
    Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123–129.
  • 25
    Schmutz G, Nelson M, Lutz T, Sheldon J, Bruno R, von Boemmel F, et al. Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. AIDS 2006; 20: 1951–1954.
  • 26
    Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. HEPATOLOGY 2006; 44: 1110–1116.
    Direct Link:
  • 27
    Benhamou Y. Hepatitis B in the HIV-coinfected patient. J Acquir Immune Defic Syndr 2007; 45(Suppl 2): S57–S65; discussion: S66–S57.
  • 28
    French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18: 1615–1627.
  • 29
    Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102: 968–975.
  • 30
    Law WP, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18: 1169–1177.
  • 31
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Bethesda, MD: Department of Health and Human Services; 2008. Available at: http://aidsinfo.nih.gov/contentfiles/adultandadolescentGI.pdf.
  • 32
    World Health Organization HIV/AIDS Programme. Antiretroviral therapy for HIV infection in adults and adolescents in resource limited settings: towards universal access. Geneva, Switzerland; 2006. Available at: http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf. Accessed June 2008.
View Full Article (HTML) Get PDF (188K)